GlassScriptPhysician profile
Elena C Coppola
NPI 1760689665
$604.37
in general payments reported to CMS, 2019-2025
14 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.43 · 2020: $112 · 2021: $130 · 2022: $14.66 · 2023: $77.36 · 2024: $116 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301 · Education: $32.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.41 |
| Education | $32.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $215.39 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $74.44 | 2021-2025 | |
| Lilly USA, LLC | $45.33 | 2024-2025 | Jaypirca, Verzenio |
| Glaxosmithkline, LLC. | $44.10 | 2024-2025 | Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $39.69 | 2020-2023 | Opdivo |
| Eisai INC. | $36.91 | 2024 | |
| Recordati_rare_diseases_inc. | $24.29 | 2023 | Sylvant |
| Servier Pharmaceuticals LLC | $21.08 | 2025 | |
| Stemline Therapeutics INC. | $20.98 | 2025 | Orserdu |
| Genentech USA, INC. | $20.85 | 2023 | Venclexta |
| Janssen Biotech, INC. | $17.66 | 2025 | Carvykti |
| Gilead Sciences, INC. | $14.66 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.56 | 2025 | |
| Kyowa Kirin, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Coppola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.